Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Volkswagen Just Revealed a Massive Range-Extended SUV for China, and America Isn’t Getting It - 2Several Israelis attempt to cross into Gaza, escorted back to Israel by IDF
- 3Vietnam rethinks its flood strategy as climate change drives storms and devastation
- 42026 will be the year NASA astronauts fly around the moon again — if all goes to plan
- 5Soldiers seize power in Guinea-Bissau and detain the president
- Israel and Iran continue tit-for-tat attacks
- Historic underwater structure discovered by divers off French coast
- Pick Your #1 Kind Of Bread
- Russia Establishing Long-Range Drone Bases In Belarus, Warns Ukraine
- 6 Well known Nissan Vehicles in the U.S.
- The most effective method to Use an Internet Showcasing Degree for Advanced Predominance
- Home Remodel Administrations: Change Your Residing Space
- Collierville residents with no power as temperatures plunge
- Exploring the Difficulties of Co-Nurturing: Individual Bits of knowledge
